STOCK TITAN

[SCHEDULE 13G/A] Insmed, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

JPMorgan Chase & Co. filed an amendment to Schedule 13G reporting beneficial ownership of 23,014,584 shares of Insmed Incorporated common stock (CUSIP 457669307), representing 10.8% of the class. The filing breaks down voting and dispositive powers: 20,997,990 shares with sole voting power and 22,971,006 shares with sole dispositive power; smaller amounts are held with shared powers. The filing lists affiliated entities through which holdings are held, including J.P. Morgan Trust Company of Delaware, J.P. Morgan Securities LLC, JPMorgan Chase Bank NA, and various asset management and international affiliates. The filing certifies the shares are held in the ordinary course of business and not for the purpose of influencing control.

JPMorgan Chase & Co. ha presentato un emendamento al Schedule 13G per segnalare la titolarità effettiva di 23.014.584 azioni ordinarie di Insmed Incorporated (CUSIP 457669307), pari al 10,8% della classe. Il documento dettaglia i poteri di voto e dispositivi: 20.997.990 azioni con potere di voto esclusivo e 22.971.006 azioni con potere dispositivo esclusivo; importi minori sono detenuti con poteri condivisi. Vengono inoltre elencate le entità affiliate tramite cui sono detenute le partecipazioni, tra cui J.P. Morgan Trust Company of Delaware, J.P. Morgan Securities LLC, JPMorgan Chase Bank NA e varie affiliate di gestione patrimoniale e internazionali. La dichiarazione certifica che le azioni sono detenute nell'ordinaria attività commerciale e non ai fini di influenzare il controllo.

JPMorgan Chase & Co. presentó una enmienda al Schedule 13G notificando la propiedad de beneficiario de 23.014.584 acciones ordinarias de Insmed Incorporated (CUSIP 457669307), que representan el 10,8% de la clase. El informe desglosa los poderes de voto y disposición: 20.997.990 acciones con poder de voto exclusivo y 22.971.006 acciones con poder dispositive exclusivo; cantidades menores están con poderes compartidos. Se enumeran las entidades afiliadas a través de las cuales se mantienen las participaciones, incluidas J.P. Morgan Trust Company of Delaware, J.P. Morgan Securities LLC, JPMorgan Chase Bank NA y diversas filiales de gestión de activos e internacionales. La presentación certifica que las acciones se poseen en el curso normal del negocio y no con la intención de influir en el control.

JPMorgan Chase & Co.는 Schedule 13G 수정서를 제출하여 Insmed Incorporated 보통주(CUSIP 457669307) 23,014,584주, 즉 해당 종류의 10.8%에 대한 실질적 소유를 보고했습니다. 제출서에는 의결권 및 처분권이 구분되어 기재되어 있으며, 단독 의결권이 있는 주식은 20,997,990주, 단독 처분권이 있는 주식은 22,971,006주입니다. 일부 소량은 공동 권한으로 보유되어 있습니다. 보유가 이루어지는 계열사로는 J.P. Morgan Trust Company of Delaware, J.P. Morgan Securities LLC, JPMorgan Chase Bank NA 및 여러 자산운용·국제 계열사가 나열되어 있습니다. 제출서는 해당 주식이 통상적인 영업 과정에서 보유된 것이며 지배권 행사 목적이 아님을 증명합니다.

JPMorgan Chase & Co. a déposé un amendement au Schedule 13G signalant la propriété bénéficiaire de 23 014 584 actions ordinaires d'Insmed Incorporated (CUSIP 457669307), soit 10,8% de la catégorie. le document détaille les pouvoirs de vote et de disposition : 20 997 990 actions avec pouvoir de vote exclusif et 22 971 006 actions avec pouvoir de disposition exclusif ; de plus faibles montants sont détenus avec des pouvoirs partagés. Sont listées les entités affiliées par lesquelles les participations sont détenues, notamment J.P. Morgan Trust Company of Delaware, J.P. Morgan Securities LLC, JPMorgan Chase Bank NA et diverses filiales de gestion d'actifs et internationales. Le dépôt certifie que les actions sont détenues dans le cadre normal des affaires et non dans le but d'influencer le contrôle.

JPMorgan Chase & Co. hat eine Änderung zu Schedule 13G eingereicht und damit das wirtschaftliche Eigentum an 23.014.584 Stammaktien von Insmed Incorporated (CUSIP 457669307) gemeldet, was 10,8% der Klasse entspricht. Die Einreichung teilt die Stimm- und Verfügungsbefugnisse auf: 20.997.990 Aktien mit alleinigem Stimmrecht und 22.971.006 Aktien mit alleiniger Verfügungsbefugnis; kleinere Beträge werden mit geteilten Rechten gehalten. Aufgeführt sind die verbundenen Unternehmen, über die die Beteiligungen gehalten werden, darunter J.P. Morgan Trust Company of Delaware, J.P. Morgan Securities LLC, JPMorgan Chase Bank NA sowie verschiedene Asset-Management- und internationale Tochtergesellschaften. Die Meldung bestätigt, dass die Aktien im normalen Geschäftsbetrieb gehalten werden und nicht zum Zweck der Einflussnahme auf die Kontrolle dienen.

Positive
  • Transparent disclosure of a material institutional position (23,014,584 shares; 10.8% of class)
  • Clear breakdown of voting and dispositive powers, aiding investor understanding of who controls votes
Negative
  • None.

Insights

TL;DR: A large institutional holder disclosed a 10.8% stake in INSM, primarily held with sole voting and dispositive power across JPMorgan entities.

JPMorgan Chase & Co.'s Schedule 13G/A is a routine institutional ownership disclosure showing a significant, but passive, stake in Insmed. The breakdown of sole voting and dispositive powers suggests centralized control of voting decisions within JPMorgan affiliates while other subsidiaries may hold interests for clients or custody. The filing names multiple subsidiaries that hold the securities, indicating a combination of custody, proprietary, and asset-management activities. No indication is given of activist intent; the certification asserts ordinary-course holdings.

TL;DR: This is a standard 13G/A disclosure reflecting institutional ownership without claimed intent to influence control.

The amendment consolidates identification of reporting persons and affiliated subsidiaries, clarifying which JPMorgan entities are associated with the reported position. From a governance perspective, the filing signals a sizable shareholder whose voting power is primarily held sole by JPMorgan, which could matter in proxy contexts. However, the statement explicitly disclaims acquisition for control purposes, consistent with a passive investor classification under Rule 13d-1(b). No governance actions or arrangements are disclosed.

JPMorgan Chase & Co. ha presentato un emendamento al Schedule 13G per segnalare la titolarità effettiva di 23.014.584 azioni ordinarie di Insmed Incorporated (CUSIP 457669307), pari al 10,8% della classe. Il documento dettaglia i poteri di voto e dispositivi: 20.997.990 azioni con potere di voto esclusivo e 22.971.006 azioni con potere dispositivo esclusivo; importi minori sono detenuti con poteri condivisi. Vengono inoltre elencate le entità affiliate tramite cui sono detenute le partecipazioni, tra cui J.P. Morgan Trust Company of Delaware, J.P. Morgan Securities LLC, JPMorgan Chase Bank NA e varie affiliate di gestione patrimoniale e internazionali. La dichiarazione certifica che le azioni sono detenute nell'ordinaria attività commerciale e non ai fini di influenzare il controllo.

JPMorgan Chase & Co. presentó una enmienda al Schedule 13G notificando la propiedad de beneficiario de 23.014.584 acciones ordinarias de Insmed Incorporated (CUSIP 457669307), que representan el 10,8% de la clase. El informe desglosa los poderes de voto y disposición: 20.997.990 acciones con poder de voto exclusivo y 22.971.006 acciones con poder dispositive exclusivo; cantidades menores están con poderes compartidos. Se enumeran las entidades afiliadas a través de las cuales se mantienen las participaciones, incluidas J.P. Morgan Trust Company of Delaware, J.P. Morgan Securities LLC, JPMorgan Chase Bank NA y diversas filiales de gestión de activos e internacionales. La presentación certifica que las acciones se poseen en el curso normal del negocio y no con la intención de influir en el control.

JPMorgan Chase & Co.는 Schedule 13G 수정서를 제출하여 Insmed Incorporated 보통주(CUSIP 457669307) 23,014,584주, 즉 해당 종류의 10.8%에 대한 실질적 소유를 보고했습니다. 제출서에는 의결권 및 처분권이 구분되어 기재되어 있으며, 단독 의결권이 있는 주식은 20,997,990주, 단독 처분권이 있는 주식은 22,971,006주입니다. 일부 소량은 공동 권한으로 보유되어 있습니다. 보유가 이루어지는 계열사로는 J.P. Morgan Trust Company of Delaware, J.P. Morgan Securities LLC, JPMorgan Chase Bank NA 및 여러 자산운용·국제 계열사가 나열되어 있습니다. 제출서는 해당 주식이 통상적인 영업 과정에서 보유된 것이며 지배권 행사 목적이 아님을 증명합니다.

JPMorgan Chase & Co. a déposé un amendement au Schedule 13G signalant la propriété bénéficiaire de 23 014 584 actions ordinaires d'Insmed Incorporated (CUSIP 457669307), soit 10,8% de la catégorie. le document détaille les pouvoirs de vote et de disposition : 20 997 990 actions avec pouvoir de vote exclusif et 22 971 006 actions avec pouvoir de disposition exclusif ; de plus faibles montants sont détenus avec des pouvoirs partagés. Sont listées les entités affiliées par lesquelles les participations sont détenues, notamment J.P. Morgan Trust Company of Delaware, J.P. Morgan Securities LLC, JPMorgan Chase Bank NA et diverses filiales de gestion d'actifs et internationales. Le dépôt certifie que les actions sont détenues dans le cadre normal des affaires et non dans le but d'influencer le contrôle.

JPMorgan Chase & Co. hat eine Änderung zu Schedule 13G eingereicht und damit das wirtschaftliche Eigentum an 23.014.584 Stammaktien von Insmed Incorporated (CUSIP 457669307) gemeldet, was 10,8% der Klasse entspricht. Die Einreichung teilt die Stimm- und Verfügungsbefugnisse auf: 20.997.990 Aktien mit alleinigem Stimmrecht und 22.971.006 Aktien mit alleiniger Verfügungsbefugnis; kleinere Beträge werden mit geteilten Rechten gehalten. Aufgeführt sind die verbundenen Unternehmen, über die die Beteiligungen gehalten werden, darunter J.P. Morgan Trust Company of Delaware, J.P. Morgan Securities LLC, JPMorgan Chase Bank NA sowie verschiedene Asset-Management- und internationale Tochtergesellschaften. Die Meldung bestätigt, dass die Aktien im normalen Geschäftsbetrieb gehalten werden und nicht zum Zweck der Einflussnahme auf die Kontrolle dienen.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G



JPMORGAN CHASE & CO.
Signature:Rachel Tsvaygoft
Name/Title:Vice President
Date:09/04/2025

FAQ

How many shares of INSM does JPMorgan Chase & Co. report owning?

The filing reports beneficial ownership of 23,014,584 shares of INSM common stock.

What percentage of Insmed (INSM) does JPMorgan's holding represent?

The reported stake represents 10.8% of the class.

Does the filing indicate JPMorgan intends to influence control of Insmed?

No; the certification states the securities are held in the ordinary course of business and not to change or influence control.

Which JPMorgan subsidiaries are identified as holding the securities?

Identified entities include J.P. Morgan Trust Company of Delaware, J.P. Morgan Securities LLC, JPMorgan Chase Bank, N.A., JPMorgan Asset Management (UK) Limited, J.P. MORGAN SE, J.P. Morgan (Suisse) SA, J.P. Morgan Investment Management Inc., J.P. Morgan Private Investments Inc., and 55I, LLC.

Who signed the Schedule 13G/A and when was it signed?

The filing is signed by Rachel Tsvaygoft, Vice President, dated 09/04/2025.
Insmed Inc

NASDAQ:INSM

INSM Rankings

INSM Latest News

INSM Latest SEC Filings

INSM Stock Data

34.94B
208.93M
0.65%
101.25%
5%
Biotechnology
Pharmaceutical Preparations
Link
United States
BRIDGEWATER